Zacks.com on MSN4h
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
cirm.ca.gov4h
CIRM Awards Nearly $100 Million to Boost Discovery, Translational, and Clinical Disease Research
South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
BioSpace6h
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
FDA approves new type of nonopioid painkiller for acute pain
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...